Fifth Third Bancorp Summit Therapeutics Inc. Transaction History
Fifth Third Bancorp
- $27.3 Billion
- Q3 2024
A detailed history of Fifth Third Bancorp transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Fifth Third Bancorp holds 200 shares of SMMT stock, worth $3,754. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200Holding current value
$3,754% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
193Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$458 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$205 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$148 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$102 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$65.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.78B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...